Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa

AIDS

Volumn 22, Issue 15, 2008, Pages 1897-1908

  Lawn, Stephen D ^a,b   Harries, Anthony D ^b,c,d   Anglaret, Xavier ^e,f   Myer, Landon ^a,g   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MINISTRY OF HEALTH   (Malawi)

^d FAMILY HEALTH INTERNATIONAL   (United States)

^e Programme PAC CI   (United States)

^f INSERM   (France)

^g Columbia University ^*  (United States)

Author keywords

Africa; AIDS; Antiretroviral treatment; Death; Highly active antiretroviral therapy; HIV; Mortality

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; FLUCONAZOLE; ISONIAZID; NEVIRAPINE; RIFAMPICIN; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA SOUTH OF THE SAHARA; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHRONIC DIARRHEA; CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; DEVELOPED COUNTRY; EARLY DIAGNOSIS; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE FINANCING; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPOSI SARCOMA; LACTIC ACIDOSIS; LIVER TOXICITY; MONOTHERAPY; MORTALITY; PESSIMISM; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; SEPSIS; STEVENS JOHNSON SYNDROME; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; WASTING SYNDROME; WORLD HEALTH ORGANIZATION;

AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; DELIVERY OF HEALTH CARE; EARLY DIAGNOSIS; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 53549132522     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830007cd     Document Type: Review

References (92)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten CA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Egger M, May M, Chene C, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1 -infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
4. UNAIDSAVHO. AIDS epidemic update 2007. http://data.unaids.org/pub/ EPISIides/2007/2007_epiupdate_en.pdf.
5. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report; April 2007. Geneva: WHO. http://www.who.int/hiv/toronto2006/towardsuniversalaccess.pdf. [Accessed 24 April 2007]
6. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
7. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006; 367:1870-1872.
8. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10000 adults in Cote D'Ivoire: two-year outcomes and determinants. AIDS (in press).
9. Bekker LG, Myer L, OrrelI C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Air Med J 2006; 96:315-320.
10. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
11. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, et al. Initial response to highly active antiretroviral therapy in HIV-1 C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40:336-343.
12. Braitstein P, Brinkhof MW, Dabis F, Schechter M,Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
13. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224.
14. Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, Platt RW, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2006; 3:e4.
15. Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 2006; 11:63-72.
16. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-1153.
17. WHO/UNAIDS. Press release: HIV infection rates decreasing in several countries but global number of people living with HIV continues to rise; November 2005. http://www.who.int/hiv/epiupdate2005/en/print.html. [Accessed 27 March 2006].
18. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
19. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
20. Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, Weigel R, et al. Outcomes of tuberculosis patients who start antiretroviral therapy under routine programme conditions in Malawi. Int J Tuberc Lung Dis 2007; 11:412-416.
21. El-Sadr W, EIul B, Hawken M, Lima J, Macharaia D, Oluyden B, et al. HIV care and treatment in resource-limited settings: challenges and outcomes. Programme & Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles [abstract 534].
22. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
23. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776.
24. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20:1181-1189.
25. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
26. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
27. Anglaret X, Toure S, Gourvellec G, Tchehy A, Zio L, Zaho M, et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa. J Acquir Immune Defic Syndr 2004; 35:320-323.
28. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 2007; 85:550-554.
29. Bisson G, Ndwapi N, Rollins C, Avalos A, Gross R, Bellamy S, et al. zHigh rates of death among patients lost to follow-up in Botswana's National ART Program: implications for monitoring and evaluation. Programme & Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles [abstract 537].
30. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008; 168:86-93.
31. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 2003; 17 (Suppl 3):S5-S15.
32. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Toure S, Danel C, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther 2003; 8:385-393.
33. Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, Wood R. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS 2004; 18:1159-1168.
34. De laco G, Zombre M, Carvalho AC, Capone S, Some E, Pietra V, et al. Factors predicting early death in a cohort of patients with HIV/AIDS in Burkina Faso: the need for earlier diagnosis and antiretroviral treatment (ART). Abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007. Sydney, Australia: International AIDS Society, [abstract WEPEB053].
35. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21:2483-2491.
36. Jerene D, Endale A, Hailu Y, Lindtjorn B. Predictors of early death in a cohort of Ethiopian patients treated with HAART. BMC Infect Dis 2006; 6:136.
37. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355-2360.
38. Johannessen A, Naman E, Matee M, Gundersen SG, Bruun JN. Risk factors for early mortality on antiretroviral treatment in a rural hospital in Tanzania. Abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007. Sydney, Australia: International AIDS Society [abstract WEPEB054].
39. Bajunirwe F, Arts EJ, Tisch DJ, Debanne SM, Sethi AK. Survival, adherence to care and antiretroviral treatment (ART) among HIV-infected adults in rural Western Uganda. Abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007. Sydney, Australia: International AIDS Society [abstract WEPEB049].
40. Moore D, Yiannoutos C, Musick B, Downing R, Were W, Degerman R, et al. Determinants of mortality among HIV-infected individuals receiving home-based ART in rural Uganda. Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles, USA [abstract 34].
41. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhate N, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005; 38:14-17.
42. NachegaJB, Hislop M, Dowdy DW, LoM, Omer SB, Regensberg L, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006; 43:78-84.
43. Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 2006; 6:59.
44. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-2195.
45. Bennett KK, DeGruttola VG, Marschner IC, Havlir DV, Richman DD. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31:20-26.
46. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.
47. Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21:713-719.
48. Lawn SD, Myer L, Bekker LG, Wood R. Early mortality in patients with HIV-associated tuberculosis in Africa: implications for time to initiation of treatment. Programme & Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (CROI); February 2007; Los Angeles, USA. [abstract 0-126].
49. Zachariah R, Fitzgerald M, Massaquoi M, Acabu A, Chilomo D, Salaniponi FM, et al. Does antiretroviral treatment reduce case fatality among HIV-positive patients with tuberculosis in Malawi? Int J Tuberc Lung Dis 2007; 11:848-853.
50. Lucas SB, Hounnou A, Koffi K, Beaumel A, Andoh J, De Cock KM. Pathology of paediatric human immunodeficiency virus infections in Cote d'Ivoire. East Afr Med J 1996; 73:S7-S8.
51. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007; 12:929-935.
52. Kambugu A, Castelnuovo B, Wandera B, Kiragga A, Kamya M. Antiretroviral therapy in an urban African cohort does not prevent significant early mortality. Abstracts oi the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007. Sydney, Australia: International AIDS Society [abstract WEPEB055].
53. Rana F, Hawken MP, Meme HK, Chakaya JM, Githui WA, Odhiambo JA, et al. Autopsy findings in HIV-1 -infected adults in Kenya. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:83-85.
54. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993; 7:1569-1579.
55. Lucas SB, De Cock KM, Hounnou A, Peacock C, Diomande M, Honde M, et al. Contribution of tuberculosis to slim disease in Africa. BMI 1994; 308:1531-1533.
56. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
57. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341.
58. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53:357-363.
59. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 19:2050-2052.
60. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Iniect Dis 2006; 43:1069-1073.
61. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.
62. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002; 35:e128-e133.
63. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043-1049.
64. Anglaret X, Messou E, Ouassa T, Toure S, Dakoury-Dogbo N, Combe P, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003; 17:575-584.
65. Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 2006; 42:29-35.
66. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989.
67. van Oosterhout JJ, Laufer MK, Graham SM, Thumba F, Perez MA, Chimbiya N, et al. A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. J Acquir Immune Defic Syndr 2005; 39:626-631.
68. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367:1256-1261.
69. Mwaungulu FB, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004; 82:354-363.
70. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-829.
71. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Air Med J 2006; 96:722-724.
72. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 2005; 10:615-624.
73. Boulle A, Orrell C, Kaplan R, Van Cutsem G, McNally M, Hildebrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antiv Ther 2007; 12:753-760.
74. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308.
75. World Health Organisation. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. Recommendations for a public health approach. Geneva: World Health Organisation; 2006.
76. Lowrance D, Makombe S, Clin D, Harries A, Yu J, berle-Grasse J, et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 2007 [Epub ahead of print].
77. Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007; 196 (Suppl 1):S52-S62.
78. World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach; executive summary. Geneva: World Health Organisation; 2002.
79. World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach [revised 2003]. Geneva: World Health Organisation; 2002.
80. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach [revised 2006]. Geneva: World Health Organisation; 2006.
81. Lawn SD, Wood R. National adult antiretroviral therapy guidelines in South Africa: concordance with 2003 WHO guidelines? AIDS 2007; 21:121-122.
82. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006; 368:1254-1259.
83. Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175:87-93.
84. Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, Waddell R, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40:1500-1507.
85. Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196 (Suppl 1):S46-S51.
86. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.
87. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190:1670-1676.
88. Lawn SD, Wood R. When should antiretroviral treatment be started in patients with tuberculosis in South Africa? S Afr Med J 2007; 97:412-415.
89. Lawn SD, Wood R. Optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis: there may be more than one right answer. J Acquir Immune Defic Syndr 2007; 46:121-123.
90. GolubJE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441-1448.
91. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17:1369-1375.
92. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 2005; 19:1243-1249.